**Supplementary Table 1 Patient characteristics.**

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  | **Pre treatment (n=62)** | **Tamoxifen treated (n=40)** |
| **Days on treatment** |  | 20.7 days (± 9.6) |
|  |  |  |
| **Histological subtype** |  |  |
| Invasive ductal | 50 (80.6%) | 33 (82.5%) |
| Invasive lobular | 8 (12.9%) | 6 (15.0%) |
| Other | 4 (6.5%) | 1 (2.5%) |
| **Grade** |  |  |
| Good | 15 (24.2%) | 12 (30.0%) |
| Moderate | 32 (51.6%) | 21 (52.5%) |
| Poor | 8 (12.9%) | 3 (7.5%) |
| Not determined | 7(11.3%) | 4(10.0%) |
|  |  |  |
| **LN status** |  |  |
| Negative | 39 (62.9%) | 24 (60.0%) |
| Positive | 7 (11.3%) | 3 (7.5%) |
| (Sub)micrometastasis | 10 (16.1%) | 9 (22.5%) |
| Not assessed | 6 (9.7%) | 4 (10.0%) |
|  |  |  |
| **ER status** |  |  |
| Positive | 62 (100%) | 40 (100%) |
|  |  |  |
| **PR status** |  |  |
| Positive | 51 (82.3%) | 34 (85.0%) |
| Negative | 11 (17.7%) | 6 (15.0%) |
|  |  |  |
| **HER2 status** |  |  |
| Negative | 58 (93.5%) | 39 (97.5%) |
| Positive | 3 (4.8%) | 1 (2.5%) |
| Unknown | 1 (1.6%) | 0 (0%) |
| **Menopausal status** |  |  |
| Pre menopausal | 26 (41.9%) | 25 (62.5%) |
| Post menopausal | 36 (58.1%) | 15 (37.5%) |

Abbreviations: LN = Lymph Node, PR= Progesterone receptor